The sNDA submission is a major catalyst that could double REVTORPYK's addressable market. Traders should monitor for FDA acceptance of the filing and a PDUFA date, as well as any updates on the ongoing VIKTORIA-2 first-line trial.
Drug in focus
CELC drug pipeline →REVTORPYK
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
- Next catalyst
- None dated
What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $95.08entry
- T+1 · 3mo ago −1.94%α −2.59% · $93.24
- T+5 · 3mo ago +1.18%α +1.30% · $96.20
- T+20 · 8w ago −11.65%α −12.86% · $84.00
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation. This follows the drug's recent FDA approval on July 14, 2026, for the PIK3CA wild-type population. The sNDA is supported by Phase 3 VIKTORIA-1 data showing a 50% reduction in the risk of disease progression or death versus alpelisib, potentially doubling the drug's addressable patient population.
Key Facts
- Celcuity submitted an sNDA to the FDA for REVTORPYK (gedatolisib) for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
- The sNDA is supported by the Phase 3 VIKTORIA-1 trial, which showed the REVTORPYK-triplet reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; p<0.0001).
- Median progression-free survival (PFS) was 11.1 months with the REVTORPYK-triplet vs. 5.6 months with alpelisib plus fulvestrant.
- REVTORPYK was already approved by the FDA on July 14, 2026, for the PIK3CA wild-type population, and this sNDA seeks to expand the label to include PIK3CA mutant patients.
- Approximately 40% of HR+/HER2- breast cancers have PIK3CA mutations, potentially doubling the drug's addressable patient population.
Financial Impact
Expanding the addressable patient population by approximately 40% (PIK3CA mutant share of HR+/HER2- breast cancer) could significantly increase peak revenue potential for REVTORPYK.
Risk Factors
- FDA may issue a Complete Response Letter (CRL) or require additional data before approval.
- Competition from other PI3K inhibitors (e.g., alpelisib, inavolisib) could limit market share.
- Commercial launch execution risks for a drug recently approved in a narrower indication.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-365975 |
| Document: 0001193125-26-365975-index.html | 0001193125-26-365975 |
| Document: 0001193125-26-365975.txt | 0001193125-26-365975 |
Track record
26 reports on CELC
6 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers